Saturday, November 21, 2026
23.3 C
Bengaluru

Analysis of the Fastest Growing Companies and Therapy Areas in IPM – MAT Dec’24

  1. Growth Performance of Top 50 Companies in IPM (MAT Dec’24)

The top 50 pharmaceutical companies in the Indian Pharmaceutical Market (IPM) have grown significantly in various zones (West, South, North, and East). The following key insights emerge:
• The top 30 cities contributed 34% to IPM Sales for MAT Dec’24.
• The top cities grew at 8.5%, slightly higher than the overall IPM growth of 7.6%.
• Among mega metros, Delhi was the fastest-growing at 12.5%, followed by Chennai (11.6%) and Hyderabad (10.5%).
• Fastest-growing cities: Pune, Agra, Lucknow, Nashik, and Delhi saw the highest growth in demand.
• 13 out of the top 30 metros grew faster than the overall IPM, while 17 metros had growth equal to or lower than 7.6%.
• Reliance Life Sciences, Fresenius Kabi, and Merck Specialities were the fastest-growing in different regions, with growth rates exceeding 30-40%.

  1. Top 20 Fastest-Growing Companies by Zone

Each region showed distinct trends in terms of growth and key players:
• West Zone: AstraZeneca (28.6%), La Renon Healthcare (23.0%), Samarth Pharma (20.8%)
• South Zone: Reliance Life Sciences (47.6%), Fresenius Kabi (42.3%), Merck Specialities (30.9%)
• North Zone: AstraZeneca (37.7%), Bayer Pharma (33.9%), Aareen Healthcare (28.7%)
• East Zone: Hetero Healthcare (19.4%), Natco Pharma (18.9%), Corona Remedies (14.8%)

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img